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Bone turnover and 1,25-dihydroxycholecakiferol during treatment
with phosphate binders. The effect of dietary phosphate restriction with
high-dose aluminium hydroxide or calcium carbonate on bone disease
assessed by histomorphometry and on the plasma levels of 1,25-
dihydroxycholecalciferol was investigated in 12 children with chronic
renal failure (GFR 8 to 45 ml/min/l.73 m2, ageS to IS years) over a one
year period. Prior to treatment patients had biochemical and histolog-
ical hyperparathyroidism with greatly increased bone formation rates.
During treatment, plasma phosphate levels decreased from the upper to
the lower limit of normal for age (pre, 1.69 0.06mmol/liter; 6 months,
1.28 0.06 mmol/liter; I year, 1.34 0.06 nimol/liter; P < 0.01).
Circulating I ,25-dihydroxycholecalciferol rose to supranormal levels
within three months and remained high throughout the period of study
(pre, 96 32 pmol/liter; 6 months, 144 46 pmol/liter; 1 year, 169 53
pmol/liter; P < 0.001). Significant falls in bone formation rate at tissue
and cellular levels (P < 0.005) and in total resorption surface (P <
0.005) were observed. A mild mineralization defect present before
treatment worsened, with a decrease in mineral appositional rate (P <
0.01) and increase in mineralization lag time (P < 0.01). Staining for
aluminum in post-treatment biopsies was positive in 9 of II cases.
Phosphate restriction produced suppression of biochemical and histo-
logical hyperparathyroidism and sustained elevation of circulating
I ,25-dihydroxycholecalciferol. The adverse changes in bone mineral-
ization may be related to aluminium hydroxide therapy; calcium car-
bonate is therefore recommended.
Renal osteodystrophy is common in children with chronic
renal failure and secondary hyperparathyroidisin; impaired
vitamin D metabolism plays a major role in its pathogenesis [1].
Aluminium intoxication may contribute in some cases [2].
Oversecretion of parathyroid hormone (PTH) is also implicated
in the development of glucose intolerance and other sequelae of
the uraemic state [3—5]. PTH secretion can be suppressed by
elevation of the extracellular fluid ionised calcium concentra-
tion or by the action of I ,25-dihydroxycholecalciferol either
acting directly on the parathyroid gland or via increased intes-
tinal calcium absorption [6—8]. The extracellular fluid ionized
calcium level may be reduced in uremia by, among other
factors, hyperphosphatemia [6, 7]. Circulating 1,25-dihydroxy-
cholecalciferol is known to be inappropriately reduced even in
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moderate chronic renal failure [9, 10]. Studies in experimental
animals and in normal and uremic man have shown that
restricting the dietary intake of phosphorus for periods up to a
few weeks results in an increase in the production rate and the
circulating levels of 1,25-dihydroxycholecalciferol [11—16]. It is
not known whether such an effect can be maintained during
prolonged treatment. We have recently shown that secondary
hyperparathyroidism can be suppressed for extended periods
by dietary phosphate restriction with high dose phosphate
binders in children with chronic renal failure [17]. The present
report examines the effect of the treatment on bone disease
assessed by histomorphometry and on vitamin D in the same
group of patients.
Methods
We studied 12 patients with chronic renal failure aged 5 to 15
years (mean II years), GFR 8 to 45 mI/mm/I .73 m2. There was
no change in renal function during the period of study (mean
GFR before treatment 27 mI/mm/I .73 m2, after treatment 26
ml/min/t.73 m2). Clinical data on these patients have been
published before as have details of the treatment regimen [17].
Following an initial study period of three months without
phosphate binders, patients were randomly allocated to treat-
ment with either aluminium hydroxide or calcium carbonate.
The dose of binder was increased until the plasma phosphate
approached the lower limit of the normal range for age. Patients
were maintained on one binder for six months and then crossed
over to the other therapy. Dihydrotachysterol (0.25 mg/m2/day)
was given for six months before entry into the study and for the
whole study period. Monthly blood samples for iPTH, phos-
phate and routine biochemistry were taken in the morning after
an overnight fast. Plasma I ,25-dihydroxycholecalciferol and
25-hydroxycholecalciferol were measured at three monthly
intervals. Transiliac bone biopsies were obtained with a Bordier
trephine (8 mm internal diameter) under a short general anaes-
thetic before and after 12 months treatment with high dose
phosphate binders. Labelling at the calcification front was
achieved using two courses of demethyichlortetracycline (300
mg bd for 2 days) ten days apart, the second course being three
to five days before biopsy. Satisfactory biopsies before and
after treatment were obtained from II of the 12 patients.
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Biochemical assays
Methods for the estimation of plasma and urinary phosphate,
calcium, creatinine, serum parathyroid hormone and urinary
cAMP have been described previously [17].
Two milliliter plasma samples for I ,25-dihydroxycholecalci-
ferol and 25-hydroxycholecalciferol estimation were extracted
and concentrated using C18 Sep-Pak cartridges (Waters Asso-
ciates, Milford, Massachusetts, USA). The cholecalciferol
metabolites were separated by high performance liquid chro-
matography (HPLC) on a 25 cm silica column (Zorbax-Si!, E. I.
Du Pont de Nemours and Co., Wilmington, Delaware, USA)
with methanol:isopropanol:n-hexane 4.5:4.5:91 as mobile
phase. About 1500 dpm each of chromatography purified,
tritiated 25-hydroxycholecalciferol and I ,25-dihydroxychole-
calciferol were added to the plasma before extraction to assess
recovery, which averaged 60%. Fractions containing 25-hy-
droxycholecalciferol were assayed by HPLC on a 12.5cm silica
column, mobile phase 2:2:96 methanol:isopropanol:n-hexane,
using ultraviolet absorbance detection at 265 nm and compari-
son with appropriate 25-hydroxycholecalciferol standards. This
chromatographic system separates 25-hydroxycholecalciferol
from 25-hydroxyergocalciferol. Fractions containing 1,25-dihy-
droxycholecalciferol were quantitated by radioimmunoassay
using an antiserum reacting with metabolites of cholecalciferol
but not ergocalciferol (Bioanalysis Ltd., Cardiff, UK) [18] No
cross reaction with dihydrotachysterol or its metabolites was
detected under these conditions. The intra-assay coefficient or
variation for 25-hydroxycholecalciferol was 5.0% at a level of
32 nmol/liter while that for I ,25-dihydroxycholecalciferol was
8.5% at a level of 72 pmol/liter. Inter-assay variations were
6.6% and 12.0%, respectively. The normal range for 1,25-dihy-
droxycholecalciferol was 74 to 118 pmol/liter while that for
25-hydroxycholecalciferol was 20 to 100 nmol/liter. Samples
were obtained from eight normal children randomly throughout
the year. These normal values are similar to previously pub-
lished data [191.
Histomorphornetry
Biopsy specimens were fixed in 10% phosphate-buffered
formalin (pH 7) and embedded in methyl methacrylate. Non-
consecutive 8-sm sections were cut with a Jung K microtome
and stained with hematoxylin and eosin, or by the von Kossa
technique using a van Gieson counterstain, or with solochrome
azurine to stain for aluminium. Thirteen im thick unstained
sections were prepared for fluorescence microscopy. Measure-
ments of trabecular bone volume, osteoid volume, and surface
and total resorption surface were made using a Zeiss graticule
containing 25 points and 7 parallel lines, The distance between
the two tetracycline labels were measured using an eye piece
micrometer. Measurements of mean osteoid seam width and
tetracycline labelled surfaces were performed on an IBAS II
image analyzer (Kontron, West Germany). Measurements were
made without knowledge of patient status. Magnifications given
are the minimum used; higher magnifications were used where
appropriate.
The following indices were obtained by measurement or
calculation:
Total trabecular hone volume (TBV; %). The total trabecular
bone volume, unmineralized and mineralized, expressed as a
percentage of the total medullary volume and measured in an
average of 50 fields from 2 to 3 von Kossa stained sections
(magnification x 112).
Relative osteoid volume (OV; %). The percentage of total
trabecular bone volume occupied by osteoid, measured in an
average of 50 fields from 2 to 3 von Kossa stained sections
(magnification X 112).
Relative osteoid sui:ftice (OS; %). The percentage of total
trabecular bone surface covered by osteoid measured in an
average of 50 fields from 2 to 3 von Kossa stained sections
(magnification x 112).
Mean osteo,d seam width (MOSW; run). The mean width of
osteoid seams, measured in an average of fields from I von
Kossa stained section (magnification x 330).
Total resorption surface (TRS; %). The percentage of total
trabecular bone surface showing resorption cavities, measured
in an average of 25 fields from I to 2 H & E stained sections
under polarized light (magnification x 112) [20].
Mineral appositional rate in traheculur hone (MAR,;
tn/day). This was measured in 3 to 4 unstained sections using
fluorescence microscopy (magnification >< 240), following dou-
ble tetracycline labelling [211. MAR was calculated as follows
[221:
MAR = mean separation between labels >< /4
time interval between the middle of the
two labelling dose regimes (days)
Tetracycline labelled surft,ces (TLS;pm2/pii,2). The length of
the double and half the single tetracycline labelled surfaces
expressed as a decimal fraction of the total trabecular bone
surface, measured in fields from one unstained section viewed
by fluorescence microscopy (magnification X 216).
Bone firmation rate at tissue level (BFR tissue: jon3!
1tun2!day). The amount of new bone mineralized per micrometer
of trabecular bone surface/day, calculated as the product of
MAR and TLS.
Bone formation rate at basic multicellular unit level (BFR
(BMU),' wn3/jun2!day). The average amount of new mineralized
bone made per day per micrometer of osteoid covered surface,
calculated as the BFR (tissue) divided by OS/I00.
Mineralization lag time (MLT; clays). The mean time interval
between the deposition of bone matrix and its mineralization,
averaged throughout the lifespan of the osteoid seam and
calculated as the mean osteoid seam width divided by the bone
formation rate at BMU level.
The study was approved by the Guy's Hospital Ethical
Committee and informed consent was obtained from patients
and their parents. Values are expressed as the mean SD, mean
SEM, or mean and range when non-normally distributed.
Student's paired i-test, adjusted for multiplicity using the
Bonferroni correction factor where appropriate, or the Wil-
coxon Rank Sum test were used for statistical analysis of the
results.
Results
Biochemistry
The effects of phosphate restriction on plasma phosphate,
calcium and immunoreactive parathyroid hormone in this group
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Table 1. Biochemical results: Changes following one year of phosphate restriction in 12 children with chronic renal failure.
Plasma phosphate 1.68 0.34
m,no/Iliier
Plasma calcium 2.50 0.18
,n,nol/liier
Serum iPTH 1215 575
nglliter
Plasma I ,25-(OH)2D3 93 30
pinoliliter
Plasma 25-OHD3 44 34
n,no//liter
Results are mean SD.
P < 0.01 compared with basal values
of patients have been published previously [171 and are repro-
duced in Table I. Serum aluminium levels were lower during
treatment with calcium carbonate than with aluminium hydrox-
ide, but mean levels were much higher than those in non-uremic
subjects throughout the period of study (Fig. 1).
25-Hydroxycholecalciferol levels rose during treatment fol-
lowing a marked seasonal variation (Table I, Fig. 2). Circulating
I ,25-dihydroxycholecalciferol levels rose significantly within
three months of initiating treatment and remained at supranor-
mal levels throughout the year of study (Table I, Fig. 2). There
was no significant seasonal effect on I ,25-dihydroxycholecalci-
Normal
12 range
1.23 0.2la 1.33 0.25a 1.0—1.7
ferol. The 1 ,25-dihydroxycholecalciferol levels of patients on
aluminium hydroxide or calcium carbonate did not differ (mean
level on aluminium hydroxide, 136 33 pmol/liter; the level on
calcium carbonate was 130 39 pmol/Iiter).
Bone histomorphornetry
The results of one year's treatment with high dose phosphate
binders are shown in Table 2 and Figure 3. Before treatment the
biopsies showed increased bone turnover with an increased
bone formation rate at both tissue and BMU level. Pre-treat-
ment biopsies showed evidence of hyperparathyroid bone dis-
ease with increased indices of resorption. A mild mineralization
defect was apparent with a reduced mineral appositional rate
and a slightly increased mean osteoid seam width and mineral-
ization lag time. After treatment there was a highly significant
decrease in bone formation rate at the tissue and BMU level and
also in the total resorption surface (Table 2, Fig. 3). Indices
related to mineralization indicated a worsening defect with a
significant reduction in mineral appositional rate and increase in
mineralization lag time. No significant changes were observed
in trabecular bone volume, osteoid volume or mean osteoid
seam width. The changes in histomorphometric indices were
similar whether the patient had received aluminium hydroxide
or calcium carbonate for the six months before biopsy.
Solochrome azurine staining revealed weakly positive reac-
tions for aluminium in the cement lines and calcification fronts
of 9 of the II post-treatment biopsies.
Discussion
The pathogenesis of renal osteodystrophy includes secondary
hyperparathyroidism, vitamin D deficiency, chronic metabolic
acidosis and aluminium toxicity. Phosphorus retention plays a
major role in the development of secondary hyperparathyroid-
ism, both directly and through suppression of the renal synthe-
sis of I ,25-dihydroxycholecalciferol.
In this study both biochemical and histological suppression of
secondary hyperathyroidism was achieved using a simple di-
etary regime of avoiding high phosphate foods together with
high doses of phosphate binders. Following treatment there was
a highly significant reduction in serum iPTH and urinary cyclic
adenosine monophosphate excretion F171. Histologically there
was a large reduction in bone formation rates at both tissue and
BMU level. Although normal data for BFR in children is not
Months on treatment
0 3 6 9
1.35 Q34 1.29 0.24a
2.50 0.15 2.55 0.14 2.54 0.12 2.53 0.10 2.1—2.7
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131 ÷ 45 137 4l 140 soa 131 4l 75—130
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Fig. 1. Serum alumniniu,n levels JlIomm'ing six months treatment with
calcium carbonate or alum iniun? hydroxide in /2 children with chronic
renal failure. Upper limit of normal 1.4 tmol/liter (fig/liter — 23 X
.tmol/liter).
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Fig. 2. A. Plasma I ,25-dihvdroxycholecaIcifrol (I ,25-(01i)2D) (md B.
25—hvd,oxycholecalcifrrol (25—0111)3) levels before and at three monthly
intervals during phosphate restriction in /2 children ui/h chronic renal
failure. C. Plasma 25-OHD3 levels plotted against calender month.
Symbols are: () patients on no phosphate binder; (S) patients on
calcium carbonate; (C)) patients on aluminium hydroxide.
available, the pretreatment values observed were far higher
than those reported for normal adults [23]; following treatment
bone formation rates were similar to adult levels obtained using
the same histomorphometry techniques. Over the course of the
study there was a significant reduction in total resorption
surface. Pre-treatment values for total resorption surface were
higher than normal values reported in adults or children [24—281.
The information provided by measurements of total resorption
surface is limited since the rate of resorption cannot be derived
and resorption cavities may represent recent or earlier resorp-
tion. Accuracy can be improved by measurement of osteo-
clasts. However, the significant decrease following treatment
provides clear evidence of suppression of secondary hyperpara-
thyroidism.
The observed reduction in the parathyroid hormone activity
was associated with an increase in circulating 1,25-dihydroxy-
cholecalciferol maintained throughout the year of study. Direct
suppression of parathyroid hormone secretion by I ,25-dihy-
droxycholecalciferol has been demonstrated both in vitro and in
vivo [6,7, 29—31]. Increase plasma 1,25-dihydroxycholecalciferol,
associated with a parathyroid hormone independent stimulation
of 1-alpha-hydroxylase activity has been observed following
short-term phosphorus restriction in experimental animals [II,
12]. In healthy and mildly uremic subjects, a reduction in
phosphorus intake has been associated with a significant in-
crease in the serum concentration and/or rate of production of
1,25-dihydroxycholecalciferol [13—16]. We observed a rise in
I ,25-dihydroxycholecalciferol even in patients with very low
glomerular filtration rates, suggesting that the low levels of this
hormone often observed in chronic renal insufficiency may be
more the result of hyperphosphatemia than loss of renal tissue.
In our study, the initial concentrations of I ,25-dihydroxycho-
lecalciferol in the children with moderate renal insufficiency
were not significantly different from those in normal control
children. Although low levels of 1.25-dihydroxycholecalciferol
have been reported in children with moderate renal failure,
some investigators have also reported normal levels in patients
with similar renal impairment [10, 14, 16].
The simultaneous administration of dihydrotachysterol has
been reported to create methodological problems with the
measurement of I .25-dihydroxycholecalciferol by competitive
binding assay [32]. However, we detected no cross reaction
between dihydrotachysterol (or its metabolite) with I ,25-dihy-
droxycholecalciferol using radioimmunoassay.
The changes in plasma 25-hydroxycholecalciferol concentra-
tions following treatment were probably the result of seasonal
variation. Nine of the patients were recruited during the winter
months. The data in Figure 2 demonstrate the seasonal effect.
1 ,25-dihydroxycholecalciferol concentrations may be affected
by precursor supply, however, significant rises in 1,25-dihy-
droxycholecalciferol occurred with no change in 25-hydroxy-
cholecalciferol in our patients. This suggests that seasonal
changes in 25-hydroxycholecalciferol did not cause major alter-
ations in I .25-dihydroxycholecalciferol concentrations in our
patients.
In contrast to the improvement in histological indices related
to hyperparathyroidism, the mild mineralization defect present
before treatment deteriorated during the year of study. There
was a significant decrease in mineral appositional rate and
increase in mineralization lag time. Before treatment two pa-
tients had some quantitative histological osteomalacia, while
after treatment four patients had evidence of this disease.
Possible explanations include vitamin D deficiency, hypophos-
phatemia and aluminium toxicity. Vitamin D deficiency is
unlikely in our patients since I ,25-dihydroxycholecalciferol
levels were supranormal and 25-hydroxycholecalciferol levels
were normal. Recent reports have implicated hypophospha-
temia or increased aluminium intake [33, 34]. A number of
reports have appeared of associations between plasma phos-
phate and histological osteomalacia in uremic patients, for
example, Kanis et al demonstrated an inverse correlation
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Table 2. Bone results: Histomorphomctric indices before and after 12 months of phosphate restriction.
Normal
24.7 3.2
3.1 1.2
22.8 8.1
7.4 1.6
1.6 0.7
1.28 0.30
0.15 0.08
Reference
25—28
25—28
25—28
27
27,28
25,27,28
28
Pre- 12 months P
TBV 30.8 5.4 27.7 - 3.0 NS
OV c, l03 8.4 5.8 NS
Os 0/ 58.7 10.4 62.5 12.6 NS
MOSW un 13.5 + 4.5 13.4 6.2 N5
TRS % 6.4 1.7 4.7 1.3 <0.005
MAR ,wnlday 0.84 0.15 0.63 0.12 <0.01
TLS pin2/p.,n2 0.367 0.123 0.179 0.087 <0.001
BFR (tissue) 0.315 0.147 0.114 0.064 <0.002
p.nrdlpjn2/da%
BFR (BMU) 0.551 + 0.283 0.181 0.101 <0.005
p.in3/p.in2/day
MLT day 21.3(13—80) 80.0(32—149) <0.0!
Results are mean so or mean and range. Normal data are from publications indicated.
C
A 1.2
P<0.01
1.0
E 0.1
a.
a:
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0.3
Time, months
D
150
100
I-
-J
50
P<0.01
012
I P<0.01
0 12
0 12
P<0.01
0 12
11.6 2.7 25,27,28
of normal, no patient's calcium x phosphate product fell below
2.5 at any time during the study. Impaired mineralization due to
hypophosphatemia therefore seems unlikely.
Aluminium is known to have adverse effects on bone miner-
alization, and serum aluminium levels in our patients were
within the range in which aluminium-related osteodystrophy
has been reported, even when they were receiving calcium
carbonate [36, 371. The patients had been treated with alumin-
ium hydroxide before the study began, thus accounting for the
high plasma levels in patients entering the study on calcium
carbonate. Aluminium toxicity and osteomalacia have been
reported in non-dialyzed adult patients and in experimental
animal models [38—40]. The staining of aluminium in bone
sections was only weakly positive (this degree of staining has
been associated with as little as 20 g/g dried bone [34, Ellis,
HA, personal communication]), but does not provide clear
evidence of aluminium deposition at the calcification front.
While our study design does not permit firm conclusions, it
seems highly likely that aluminium toxicity was responsible for
the increasing mineralization defect we observed.
The data from the present study have important clinical
implications. A regimen of high dose phosphate binders with
only mild dietary phosphorus restriction and a small dose of
vitamin D supplement was an effective means of suppressing
secondary hyperparathyroidism assessed biochemically and
histologically, and also corrects the relative or absolute vitamin
D deficiency in children with uremia [411. Calcium carbonate
was as effective as aluminium hydroxide and should be the
phosphate binder of choice due to the problems of aluminium
toxicity exemplified by the mineralization defect we observed.
Hypercalcemic episodes were infrequent and easily controlled,
and were no more common during therapy with calcium car-
bonate than with aluminium hydroxide. Since plasma phos-
phate was kept at the lower limit of the normal range, plasma
calcium could be maintained at the higher levels needed to
suppress hyperparathyroidism in uremia [42]. The regimen,
using calcium carbonate, is well tolerated and is in routine use
in our chronic renal failure clinic [43].
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